News Release

Baxter Announces U.S. Commercial Availability of ADVATE, Signs Multi-Year Agreements with Leading U.S. Specialty Pharmacy Customers

DEERFIELD, Ill., September 12, 2003 - Following its recent U.S. launch of ADVATE, Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method, (rAHF-PFM), Baxter Healthcare Corporation (NYSE: BAX) today announced that it has signed non-exclusive multi-year agreements with several leading U.S. specialty pharmacy companies, including Accredo Health Inc. (NASDAQ: ACDO), Caremark Inc. (NYSE: CMX), Curative Health Services (NASDAQ: CURE) and Hemophilia Resources of America to dispense ADVATE for the prevention and control of bleeding episodes in people with hemophilia A.

"The availability of ADVATE in the United States is another milestone for Baxter and the hemophilia community," said Larry Guiheen, president, Biopharmaceuticals at Baxter. "For more than a decade, Baxter has dedicated itself to increasing the supply of recombinant therapy, and today, we reaffirm that commitment by bringing a strong supply of ADVATE to the U.S. hemophilia community."

ADVATE, approved by the U.S. Food and Drug Administration (FDA) on July 25, 2003 and made commercially available in late August 2003, is the first and only recombinant factor VIII made without any added human or animal plasma proteins and albumin in the cell culture process, purification and final formulation, thereby eliminating the risk of infections caused by viruses that may be carried in these proteins.

Over the past 40 years, Baxter has been a leader in providing the hemophilia community with increasingly advanced clotting therapies. In the early 1990s, Baxter launched the first recombinant factor VIII therapeutic, RECOMBINATE rAHF, which has now become the leading treatment for hemophilia A. ADVATE, Baxter's latest development, was a response to the National Hemophilia Foundation's Medical and Scientific Advisory Council (MASAC) recommendations that "all efforts should be made to remove human albumin from recombinant factor VIII products" and " increased efforts should be made to eliminate human and bovine proteins from the manufacturing process of recombinant products."

"We are pleased to work with Baxter to make this exciting new class of therapy available to people with hemophilia A," said Kyle J. Callahan, president of Accredo's subsidiary Hemophilia Health Services, Inc.

"With this agreement, we underscore our focus on providing the hemophilia community with the most advanced treatments and options for their care," said A.D. Frazier, President and COO of Caremark Rx, Inc.

ADVATE is available as a single dose vial in four convenient potencies of 250, 500, 1,000 IU per vial and in a super-high potency 1,500 IU per vial, with a smaller infusion volume (5mL diluent), which means shorter infusion times for patients. ADVATE comes packaged with a 10mL syringe, butterfly bandage, alcohol swab and a patient-friendly package insert.

Side effects related to the use of ADVATE are uncommon. No serious adverse events related to treatment with ADVATE have been reported to date. Non-serious, moderate or mild related adverse events may include: a strange taste, itching at the infusion site, dizziness, headaches, catheter-related infections, hot flashes, diarrhea, lower limb edema, sweating, nausea, pain in the upper abdomen or lower chest, decreased red blood cell count, joint swelling and shortness of breath. Non-serious, but severe related adverse events may include: fever, headache and decreased coagulation factor VIII levels.

For more information and full prescribing information on ADVATE, please visit www.advate.com or call 1-888-4-ADVATE.

Baxter Healthcare Corporation is the principal domestic operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists health-care professionals and their patients with treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

Baxter, Advate and Recombinate are trademarks of Baxter International Inc. Baxter is registered in the U.S. Patent and Trademark Office.

FOR ADDITIONAL INFORMATION:

	Media Contacts: Deborah Spak, 847-948-2349 Liz Meagher, 847-948-3297 Investor Contacts: Neville Jeharajah, 847-948-2875 Mary Kay Ladone, 847-948-337